Do analysts recommend NAGE or AIFC?

Niagen Bioscience presently has a consensus target price of $10.50, indicating a potential upside of 227.10%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, equities research analysts clearly believe Niagen Bioscience is more favorable than ALT5 Sigma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Niagen Bioscience 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, NAGE or AIFC?

Niagen Bioscience has higher revenue and earnings than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Niagen Bioscience $129.42M 1.98 $17.38M $0.21 15.29 ALT5 Sigma $24.70M 2.45 -$344.51M N/A N/A

Do analysts recommend ZSQR or AIFC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, ZSQR or AIFC?

Coeptis Therapeutics has higher earnings, but lower revenue than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Coeptis Therapeutics $1.36M 198.91 -$11.92M -$2.52 N/A ALT5 Sigma $24.70M 2.45 -$344.51M N/A N/A

Do analysts recommend AIFC or QTTB?

Q32 Bio has a consensus target price of $22.33, suggesting a potential upside of 47.41%. Given Q32 Bio's stronger consensus rating and higher possible upside, analysts clearly believe Q32 Bio is more favorable than ALT5 Sigma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Q32 Bio 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has stronger valuation & earnings, AIFC or QTTB?

Q32 Bio has higher revenue and earnings than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALT5 Sigma $24.70M 2.45 -$344.51M N/A N/A Q32 Bio $53.74M 4.78 $29.82M $2.66 5.70

Is AIFC or QTTB more profitable?

Q32 Bio has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. Q32 Bio's return on equity of 149.23% beat ALT5 Sigma's return on equity. Company Net Margins Return on Equity Return on Assets ALT5 Sigma -2,483.94% -68.25% -62.43% Q32 Bio N/A 149.23% 34.50%

Do analysts rate AIFC or SRZN?

Surrozen has a consensus target price of $42.00, indicating a potential upside of 112.87%. Given Surrozen's stronger consensus rating and higher possible upside, analysts clearly believe Surrozen is more favorable than ALT5 Sigma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Surrozen 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has better earnings and valuation, AIFC or SRZN?

Surrozen has lower revenue, but higher earnings than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALT5 Sigma $24.70M 2.45 -$344.51M N/A N/A Surrozen $3.48M 65.82 -$242.03M -$37.59 N/A

Is AIFC or SRZN more profitable?

ALT5 Sigma has a net margin of -2,483.94% compared to Surrozen's net margin of -4,810.50%. Surrozen's return on equity of 0.00% beat ALT5 Sigma's return on equity. Company Net Margins Return on Equity Return on Assets ALT5 Sigma -2,483.94% -68.25% -62.43% Surrozen -4,810.50% N/A -154.08%

Do analysts recommend AIFC or IRD?

Opus Genetics has a consensus price target of $10.77, indicating a potential upside of 249.65%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts plainly believe Opus Genetics is more favorable than ALT5 Sigma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Opus Genetics 2 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 2.82

Which has preferable valuation & earnings, AIFC or IRD?

Opus Genetics has lower revenue, but higher earnings than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALT5 Sigma $24.70M 2.45 -$344.51M N/A N/A Opus Genetics $14.20M 17.91 -$49.59M -$1.33 N/A

Is AIFC or IRD more profitable?

Opus Genetics has a net margin of -892.36% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat Opus Genetics' return on equity. Company Net Margins Return on Equity Return on Assets ALT5 Sigma -2,483.94% -68.25% -62.43% Opus Genetics -892.36% -338.88% -191.21%

ALT5 Sigma (AIFC) Competitors

$0.43 -0.03 (-7.38%)

As of 07/24/2026 04:00 PM Eastern

Compare

AIFC vs. NAGE, ZSQR, QTTB, SRZN, and IRD

Should you buy ALT5 Sigma stock or one of its competitors? MarketBeat compares ALT5 Sigma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ALT5 Sigma include Niagen Bioscience (NAGE), Coeptis Therapeutics (ZSQR), Q32 Bio (QTTB), Surrozen (SRZN), and Opus Genetics (IRD). These companies are all part of the "pharmaceutical products" industry.

How does ALT5 Sigma compare to Niagen Bioscience?

Niagen Bioscience (NASDAQ:NAGE) and ALT5 Sigma (NASDAQ:AIFC) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

Niagen Bioscience has a beta of 2.09, suggesting that its stock price is 109% more volatile than the broader market. Comparatively, ALT5 Sigma has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market.

Niagen Bioscience presently has a consensus target price of $10.50, indicating a potential upside of 227.10%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, equities research analysts clearly believe Niagen Bioscience is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

15.4% of Niagen Bioscience shares are held by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are held by institutional investors. 10.0% of Niagen Bioscience shares are held by company insiders. Comparatively, 0.2% of ALT5 Sigma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Niagen Bioscience had 1 more articles in the media than ALT5 Sigma. MarketBeat recorded 2 mentions for Niagen Bioscience and 1 mentions for ALT5 Sigma. Niagen Bioscience's average media sentiment score of 1.26 beat ALT5 Sigma's score of 0.94 indicating that Niagen Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Niagen Bioscience	Positive
ALT5 Sigma	Positive

Niagen Bioscience has higher revenue and earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$129.42M	1.98	$17.38M	$0.21	15.29
ALT5 Sigma	$24.70M	2.45	-$344.51M	N/A	N/A

Niagen Bioscience has a net margin of 14.29% compared to ALT5 Sigma's net margin of -2,483.94%. Niagen Bioscience's return on equity of 22.68% beat ALT5 Sigma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	14.29%	22.68%	16.23%
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%

Summary

Niagen Bioscience beats ALT5 Sigma on 14 of the 15 factors compared between the two stocks.

How does ALT5 Sigma compare to Coeptis Therapeutics?

Coeptis Therapeutics (NASDAQ:ZSQR) and ALT5 Sigma (NASDAQ:AIFC) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

Coeptis Therapeutics has a net margin of -810.04% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%

Coeptis Therapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market. Comparatively, ALT5 Sigma has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market.

Coeptis Therapeutics has higher earnings, but lower revenue than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	$1.36M	198.91	-$11.92M	-$2.52	N/A
ALT5 Sigma	$24.70M	2.45	-$344.51M	N/A	N/A

In the previous week, Coeptis Therapeutics had 2 more articles in the media than ALT5 Sigma. MarketBeat recorded 3 mentions for Coeptis Therapeutics and 1 mentions for ALT5 Sigma. ALT5 Sigma's average media sentiment score of 0.94 beat Coeptis Therapeutics' score of 0.22 indicating that ALT5 Sigma is being referred to more favorably in the news media.

Company	Overall Sentiment
Coeptis Therapeutics	Neutral
ALT5 Sigma	Positive

13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by insiders. Comparatively, 0.2% of ALT5 Sigma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Coeptis Therapeutics beats ALT5 Sigma on 6 of the 11 factors compared between the two stocks.

How does ALT5 Sigma compare to Q32 Bio?

ALT5 Sigma (NASDAQ:AIFC) and Q32 Bio (NASDAQ:QTTB) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Q32 Bio has a consensus target price of $22.33, suggesting a potential upside of 47.41%. Given Q32 Bio's stronger consensus rating and higher possible upside, analysts clearly believe Q32 Bio is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

6.3% of ALT5 Sigma shares are held by institutional investors. Comparatively, 31.3% of Q32 Bio shares are held by institutional investors. 0.2% of ALT5 Sigma shares are held by insiders. Comparatively, 34.5% of Q32 Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Q32 Bio has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. Q32 Bio's return on equity of 149.23% beat ALT5 Sigma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%
Q32 Bio	N/A	149.23%	34.50%

ALT5 Sigma has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market. Comparatively, Q32 Bio has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

Q32 Bio has higher revenue and earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALT5 Sigma	$24.70M	2.45	-$344.51M	N/A	N/A
Q32 Bio	$53.74M	4.78	$29.82M	$2.66	5.70

In the previous week, Q32 Bio had 2 more articles in the media than ALT5 Sigma. MarketBeat recorded 3 mentions for Q32 Bio and 1 mentions for ALT5 Sigma. ALT5 Sigma's average media sentiment score of 0.94 beat Q32 Bio's score of 0.91 indicating that ALT5 Sigma is being referred to more favorably in the media.

Company	Overall Sentiment
ALT5 Sigma	Positive
Q32 Bio	Positive

Summary

Q32 Bio beats ALT5 Sigma on 12 of the 14 factors compared between the two stocks.

How does ALT5 Sigma compare to Surrozen?

ALT5 Sigma (NASDAQ:AIFC) and Surrozen (NASDAQ:SRZN) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

6.3% of ALT5 Sigma shares are owned by institutional investors. Comparatively, 66.6% of Surrozen shares are owned by institutional investors. 0.2% of ALT5 Sigma shares are owned by insiders. Comparatively, 31.7% of Surrozen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

ALT5 Sigma has a net margin of -2,483.94% compared to Surrozen's net margin of -4,810.50%. Surrozen's return on equity of 0.00% beat ALT5 Sigma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%
Surrozen	-4,810.50%	N/A	-154.08%

Surrozen has a consensus target price of $42.00, indicating a potential upside of 112.87%. Given Surrozen's stronger consensus rating and higher possible upside, analysts clearly believe Surrozen is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Surrozen	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

Surrozen has lower revenue, but higher earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALT5 Sigma	$24.70M	2.45	-$344.51M	N/A	N/A
Surrozen	$3.48M	65.82	-$242.03M	-$37.59	N/A

In the previous week, Surrozen had 2 more articles in the media than ALT5 Sigma. MarketBeat recorded 3 mentions for Surrozen and 1 mentions for ALT5 Sigma. ALT5 Sigma's average media sentiment score of 0.94 beat Surrozen's score of 0.63 indicating that ALT5 Sigma is being referred to more favorably in the media.

Company	Overall Sentiment
ALT5 Sigma	Positive
Surrozen	Positive

ALT5 Sigma has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market. Comparatively, Surrozen has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market.

Summary

Surrozen beats ALT5 Sigma on 10 of the 15 factors compared between the two stocks.

How does ALT5 Sigma compare to Opus Genetics?

ALT5 Sigma (NASDAQ:AIFC) and Opus Genetics (NASDAQ:IRD) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Opus Genetics has a consensus price target of $10.77, indicating a potential upside of 249.65%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts plainly believe Opus Genetics is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.82

Opus Genetics has a net margin of -892.36% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%
Opus Genetics	-892.36%	-338.88%	-191.21%

Opus Genetics has lower revenue, but higher earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALT5 Sigma	$24.70M	2.45	-$344.51M	N/A	N/A
Opus Genetics	$14.20M	17.91	-$49.59M	-$1.33	N/A

6.3% of ALT5 Sigma shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 0.2% of ALT5 Sigma shares are owned by company insiders. Comparatively, 11.7% of Opus Genetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Opus Genetics had 1 more articles in the media than ALT5 Sigma. MarketBeat recorded 2 mentions for Opus Genetics and 1 mentions for ALT5 Sigma. Opus Genetics' average media sentiment score of 1.07 beat ALT5 Sigma's score of 0.94 indicating that Opus Genetics is being referred to more favorably in the news media.

Company	Overall Sentiment
ALT5 Sigma	Positive
Opus Genetics	Positive

ALT5 Sigma has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

Summary

Opus Genetics beats ALT5 Sigma on 11 of the 15 factors compared between the two stocks.

Get ALT5 Sigma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIFC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIFC vs. The Competition

Export

Metric	ALT5 Sigma	FIN Industry	Finance Sector	NASDAQ Exchange
Market Cap	$65.40M	$7.21B	$14.35B	$12.26B
Dividend Yield	N/A	5.10%	5.72%	9.79%
P/E Ratio	N/A	17.22	20.42	23.71
Price / Sales	2.45	11.22	45.23	74.83
Price / Cash	N/A	49.04	19.21	59.64
Price / Book	0.05	3.26	2.25	6.07
Net Income	-$344.51M	$308.48M	$1.14B	$331.84M
7 Day Performance	-21.88%	-0.83%	-0.47%	-1.53%
1 Month Performance	-22.35%	-2.88%	1.21%	-2.46%
1 Year Performance	-93.88%	-6.30%	12.28%	13.66%

ALT5 Sigma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIFC ALT5 Sigma	0.4318 of 5 stars	$0.43 -7.4%	N/A	-93.9%	$65.40M	$24.70M	N/A	170	News Coverage
NAGE Niagen Bioscience	4.2598 of 5 stars	$3.39 -2.9%	$10.50 +209.7%	-65.4%	$269.98M	$129.42M	16.14	120	Positive News
ZSQR Coeptis Therapeutics	0.1084 of 5 stars	$4.98 -6.6%	N/A	-55.8%	$256.12M	$1.36M	N/A	2	News Coverage Short Interest Increase
QTTB Q32 Bio	4.4826 of 5 stars	$15.08 -2.1%	$22.33 +48.1%	+555.8%	$255.70M	$53.74M	5.67	39	Short Interest Increase
SRZN Surrozen	2.4167 of 5 stars	$21.72 -5.5%	$42.00 +93.4%	+123.7%	$252.17M	$7.49M	N/A	80	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIFC) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ALT5 Sigma (AIFC) Competitors

AIFC vs. NAGE, ZSQR, QTTB, SRZN, and IRD

How does ALT5 Sigma compare to Niagen Bioscience?

Summary

How does ALT5 Sigma compare to Coeptis Therapeutics?

Summary

How does ALT5 Sigma compare to Q32 Bio?

Summary

How does ALT5 Sigma compare to Surrozen?

Summary

How does ALT5 Sigma compare to Opus Genetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIFC vs. The Competition

ALT5 Sigma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ALT5 Sigma (AIFC) Competitors

AIFC vs. NAGE, ZSQR, QTTB, SRZN, and IRD

How does ALT5 Sigma compare to Niagen Bioscience?

Which has more volatility and risk, NAGE or AIFC?

Do analysts recommend NAGE or AIFC?

Do insiders & institutionals have more ownership in NAGE or AIFC?

Does the media refer more to NAGE or AIFC?

Which has stronger earnings and valuation, NAGE or AIFC?

Is NAGE or AIFC more profitable?

Summary

How does ALT5 Sigma compare to Coeptis Therapeutics?

Is ZSQR or AIFC more profitable?

Which has more risk & volatility, ZSQR or AIFC?

Which has better valuation and earnings, ZSQR or AIFC?

Does the media prefer ZSQR or AIFC?

Do insiders and institutionals have more ownership in ZSQR or AIFC?

Do analysts recommend ZSQR or AIFC?

Summary

How does ALT5 Sigma compare to Q32 Bio?

Do analysts recommend AIFC or QTTB?

Do institutionals & insiders hold more shares of AIFC or QTTB?

Is AIFC or QTTB more profitable?

Which has more volatility & risk, AIFC or QTTB?

Which has stronger valuation & earnings, AIFC or QTTB?

Does the media favor AIFC or QTTB?

Summary

How does ALT5 Sigma compare to Surrozen?

Do institutionals and insiders believe in AIFC or SRZN?

Is AIFC or SRZN more profitable?

Do analysts rate AIFC or SRZN?

Which has better earnings and valuation, AIFC or SRZN?

Does the media favor AIFC or SRZN?

Which has more volatility & risk, AIFC or SRZN?

Summary

How does ALT5 Sigma compare to Opus Genetics?

Do analysts recommend AIFC or IRD?

Is AIFC or IRD more profitable?

Which has preferable valuation & earnings, AIFC or IRD?

Do institutionals & insiders believe in AIFC or IRD?

Does the media refer more to AIFC or IRD?

Which has more volatility & risk, AIFC or IRD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIFC vs. The Competition

ALT5 Sigma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools